title: S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.
abstract: Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5% to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, surveys have shown that patients still do not received optimal treatments. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologi sche Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. They were first published in 2006 and updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate and severe plaque-type psoriasis in adults including systemic therapy, UV therapy and topical therapies. The therapeutic recommendations were developed based on the results of a systematic literature search and were finalized during a consensus meeting using structured consensus methods (nominal group process).
authors.affiliation: Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Venerologie und Allergologie, Charité- Universitätsmedizin Berlin, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Nast
authors.forename: Wolf-Henning
authors.initials: WH
authors.lastname: Boehncke
authors.forename: Ulrich
authors.initials: U
authors.lastname: Mrowietz
authors.forename: Hans-Michael
authors.initials: HM
authors.lastname: Ockenfels
authors.forename: Sandra
authors.initials: S
authors.lastname: Philipp
authors.forename: Kristian
authors.initials: K
authors.lastname: Reich
authors.forename: Thomas
authors.initials: T
authors.lastname: Rosenbach
authors.forename: Adel
authors.initials: A
authors.lastname: Sammain
authors.forename: Martin
authors.initials: M
authors.lastname: Schlaeger
authors.forename: Michael
authors.initials: M
authors.lastname: Sebastian
authors.forename: Wolfram
authors.initials: W
authors.lastname: Sterry
authors.forename: Volker
authors.initials: V
authors.lastname: Streit
authors.forename: Matthias
authors.initials: M
authors.lastname: Augustin
authors.forename: Ricardo
authors.initials: R
authors.lastname: Erdmann
authors.forename: Joachim
authors.initials: J
authors.lastname: Klaus
authors.forename: Joachim
authors.initials: J
authors.lastname: Koza
authors.forename: Siegrid
authors.initials: S
authors.lastname: Muller
authors.forename: Hans-Dieter
authors.initials: HD
authors.lastname: Orzechowski
authors.forename: Stefanie
authors.initials: S
authors.lastname: Rosumeck
authors.forename: Gerhard
authors.initials: G
authors.lastname: Schmid-Ott
authors.forename: Tobias
authors.initials: T
authors.lastname: Weberschock
authors.forename: Berthold
authors.initials: B
authors.lastname: Rzany
mesh_terms: D000287:Administration, Topical; D000328:Adult; D003879:Dermatologic Agents / Q000008:administration & dosage*; D003880:Dermatology / Q000592:standards*; D006801:Humans; D011565:Psoriasis / Q000175:diagnosis* / Q000628:therapy*; D011787:Quality of Health Care; D014467:Ultraviolet Therapy / Q000592:standards*
chemical_list: D003879:Dermatologic Agents